Download PDF
Semin Thromb Hemost 2015; 41(06): 607-614
DOI: 10.1055/s-0035-1556725
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Antiphospholipid Syndrome–Not a Noninflammatory Disease

Philip G. de Groot
1   Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Rolf T. Urbanus
1   Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
15 August 2015 (online)

    Permissions and Reprints

Abstract

The autoimmune disease antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy morbidity in patients with persistent antiphospholipid antibodies (aPLs). Although inflammation is not a key feature of the clinical presentation of the syndrome, there are indications that the inflammatory response plays an important role in APS. The major antigen of aPLs, the plasma protein β2-glycoprotein I, is involved in clearance of microparticles and in the innate immune response. In light of these physiological functions, the formation of antibodies against the protein is easily understood, as antibodies might augment the clearance reaction. In addition, inflammatory mediators are thought to play a role in the activation of leukocytes and the induction of endothelial dysfunction in APS. Moreover, evidence for a role of complement activation in the pathogenesis of the syndrome is accumulating. This review will provide an overview of current knowledge on the physiological function of β2-glycoprotein I, the formation of autoantibodies against β2-glycoprotein I and will explore the contribution of inflammation to the clinical manifestations of APS.

Keywords

inflammation - β2-glycoprotein I - infection - complement - antiphospholipid syndrome
 

  • References

  • 1 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
    CrossrefPubMedGoogle Scholar
  • 2 Galli M, Comfurius P, Maassen C , et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335 (8705) 1544-1547
    CrossrefPubMedGoogle Scholar
  • 3 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet (London, England) 1990; 366: 117-118
    PubMedGoogle Scholar
  • 4 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
    CrossrefPubMedGoogle Scholar
  • 5 Cervera R, Piette JC, Font J , et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (4) 1019-1027
    CrossrefPubMedGoogle Scholar
  • 6 Golan TD. Lupus vasculitis: differential diagnosis with antiphospholipid syndrome. Curr Rheumatol Rep 2002; 4 (1) 18-24
    CrossrefPubMedGoogle Scholar
  • 7 Lie JT. Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is the culprit and vasculitis the consort. Lupus 1996; 5 (5) 368-371
    PubMedGoogle Scholar
  • 8 Wilson WA, Gharavi AE, Koike T , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (7) 1309-1311
    CrossrefPubMedGoogle Scholar
  • 9 de Groot PG, Meijers JC. β(2)–Glycoprotein I: evolution, structure and function. J Thromb Haemost 2011; 9 (7) 1275-1284
    CrossrefPubMedGoogle Scholar
  • 10 Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999; 81 (1) 87-95
    PubMedGoogle Scholar
  • 11 Sendoel A, Hengartner MO. Apoptotic cell death under hypoxia. Physiology (Bethesda) 2014; 29 (3) 168-176
    CrossrefPubMedGoogle Scholar
  • 12 Cheng HM. Physiologic apoptosis, beta 2-glycoprotein I, and antiphospholipid autoantibodies. Am J Obstet Gynecol 1996; 175 (5) 1393
    PubMedGoogle Scholar
  • 13 Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem 1997; 272 (49) 31113-31117
    CrossrefPubMedGoogle Scholar
  • 14 Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem 1998; 273 (44) 29272-29277
    CrossrefPubMedGoogle Scholar
  • 15 Agar C, de Groot PG, Mörgelin M , et al. β2-glycoprotein I: a novel component of innate immunity. Blood 2011; 117 (25) 6939-6947
    CrossrefPubMedGoogle Scholar
  • 16 Agar C, van Os GM, Mörgelin M , et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116 (8) 1336-1343
    CrossrefPubMedGoogle Scholar
  • 17 Du VX, van Os G, Kremer Hovinga JA , et al. Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura. Br J Haematol 2012; 159 (1) 94-103
    CrossrefPubMedGoogle Scholar
  • 18 Lin F, Murphy R, White B , et al. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus 2006; 15 (2) 87-93
    CrossrefPubMedGoogle Scholar
  • 19 Poon IK, Patel KK, Davis DS, Parish CR, Hulett MD. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood 2011; 117 (7) 2093-2101
    CrossrefPubMedGoogle Scholar
  • 20 Yeaman MR, Bayer AS. Antimicrobial peptides versus invasive infections. Curr Top Microbiol Immunol 2006; 306: 111-152
    PubMedGoogle Scholar
  • 21 Nilsson M, Wasylik S, Mörgelin M , et al. The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 2008; 67 (3) 482-492
    CrossrefPubMedGoogle Scholar
  • 22 Raschi E, Chighizola CB, Grossi C , et al. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014; 55: 42-50
    CrossrefPubMedGoogle Scholar
  • 23 Fleming SD, Pope MR, Hoffman SM , et al. Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation. J Immunol 2010; 185 (10) 6168-6178
    CrossrefPubMedGoogle Scholar
  • 24 Pope MR, Bukovnik U, Tomich JM, Fleming SD. Small β2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury. J Immunol 2012; 189 (10) 5047-5056
    CrossrefPubMedGoogle Scholar
  • 25 Tomasi M, Hiromasa Y, Pope MR, Gudlur S, Tomich JM, Fleming SD. Human β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammation. Mol Immunol 2012; 52 (3-4) 207-216
    CrossrefPubMedGoogle Scholar
  • 26 Forastiero R, Martinuzzo M, de Larrañaga G, Vega-Ostertag M, Pierangeli S. Anti-β2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model. J Thromb Haemost 2011; 9 (4) 859-861
    CrossrefPubMedGoogle Scholar
  • 27 de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (4) 1540-1545
    CrossrefPubMedGoogle Scholar
  • 28 Male C, Foulon D, Hoogendoorn H , et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106 (13) 4152-4158
    CrossrefPubMedGoogle Scholar
  • 29 Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73 (1) 29-34
    PubMedGoogle Scholar
  • 30 Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000; 43 (1) 65-75
    CrossrefPubMedGoogle Scholar
  • 31 de Laat B, van Berkel M, Urbanus RT , et al. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 2011; 63 (12) 3960-3968
    CrossrefPubMedGoogle Scholar
  • 32 Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008; 7 (4) 272-277
    CrossrefPubMedGoogle Scholar
  • 33 Rose NR. Autoimmunity, infection and adjuvants. Lupus 2010; 19 (4) 354-358
    CrossrefPubMedGoogle Scholar
  • 34 van Os GM, Meijers JC, Agar Ç , et al. Induction of anti-β2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 2011; 9 (12) 2447-2456
    CrossrefPubMedGoogle Scholar
  • 35 Levine JS, Subang R, Nasr SH , et al. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006; 177 (9) 6504-6516
    CrossrefPubMedGoogle Scholar
  • 36 Andreoli L, Fredi M, Nalli C, Franceschini F, Meroni PL, Tincani A. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity 2013; 46 (5) 302-306
    CrossrefPubMedGoogle Scholar
  • 37 Dlott JS, Roubey RA. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep 2012; 14 (1) 71-78
    CrossrefPubMedGoogle Scholar
  • 38 Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24 (6) 1083-1088
    PubMedGoogle Scholar
  • 39 Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. J Thromb Haemost 2011; 9 (Suppl. 01) 275-282
    PubMedGoogle Scholar
  • 40 Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999; 341 (27) 2068-2074
    CrossrefPubMedGoogle Scholar
  • 41 Lockshin MD, Kim M, Laskin CA , et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64 (7) 2311-2318
    CrossrefPubMedGoogle Scholar
  • 42 Ruffatti A, Del Ross T, Ciprian M , et al; Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis 2011; 70 (6) 1083-1086
    CrossrefPubMedGoogle Scholar
  • 43 Pengo V, Ruffatti A, Legnani C , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
    CrossrefPubMedGoogle Scholar
  • 44 Fischetti F, Durigutto P, Pellis V , et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106 (7) 2340-2346
    CrossrefPubMedGoogle Scholar
  • 45 Cervera R, Bucciarelli S, Plasín MA , et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009; 32 (3-4) 240-245
    CrossrefPubMedGoogle Scholar
  • 46 Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177 (4) 918-923
    CrossrefPubMedGoogle Scholar
  • 47 Krikun G, Lockwood CJ, Wu XX , et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta 1994; 15 (6) 601-612
    CrossrefPubMedGoogle Scholar
  • 48 Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 2007; 9: 121-167
    CrossrefPubMedGoogle Scholar
  • 49 Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood 2011; 117 (23) 6383-6391
    CrossrefPubMedGoogle Scholar
  • 50 Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EK. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost 2002; 88 (5) 851-857
    PubMedGoogle Scholar
  • 51 Dekker RJ, van Soest S, Fontijn RD , et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood 2002; 100 (5) 1689-1698
    CrossrefPubMedGoogle Scholar
  • 52 Ramesh S, Morrell CN, Tarango C , et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest 2011; 121 (1) 120-131
    CrossrefPubMedGoogle Scholar
  • 53 Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT , et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood 2011; 117 (4) 1408-1414
    CrossrefPubMedGoogle Scholar
  • 54 Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88 (2) 245-250
    CrossrefPubMedGoogle Scholar
  • 55 Dignat-George F, Camoin-Jau L, Sabatier F , et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost 2004; 91 (4) 667-673
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124 (4) 611-622
    CrossrefPubMedGoogle Scholar
  • 57 Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153 (3) 1328-1332
    PubMedGoogle Scholar
  • 58 Redecha P, Tilley R, Tencati M , et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110 (7) 2423-2431
    CrossrefPubMedGoogle Scholar
  • 59 Xie H, Zhou H, Wang H , et al. Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 2013; 53 (3) 246-254
    CrossrefPubMedGoogle Scholar
  • 60 Erkan D, Willis R, Murthy VL , et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014; 73 (6) 1176-1180
    CrossrefPubMedGoogle Scholar
  • 61 Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174 (1) 485-490
    CrossrefPubMedGoogle Scholar
  • 62 Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008; 118 (10) 3453-3461
    PubMedGoogle Scholar
  • 63 Gladigau G, Haselmayer P, Scharrer I , et al. A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome. PLoS ONE 2012; 7 (7) e42176
    CrossrefPubMedGoogle Scholar
  • 64 Girardi G, Berman J, Redecha P , et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112 (11) 1644-1654
    CrossrefPubMedGoogle Scholar
  • 65 Sorice M, Longo A, Capozzi A , et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56 (8) 2687-2697
    CrossrefPubMedGoogle Scholar
  • 66 Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem 2004; 279 (42) 43411-43418
    CrossrefPubMedGoogle Scholar
  • 67 Hazeltine M, Rauch J, Danoff D, Esdaile JM, Tannenbaum H. Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs' and hypocomplementemia. J Rheumatol 1988; 15 (1) 80-86
    PubMedGoogle Scholar
  • 68 Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344 (14) 1058-1066
    CrossrefPubMedGoogle Scholar
  • 69 Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52 (7) 2120-2124
    CrossrefPubMedGoogle Scholar
  • 70 Carrera-Marín A, Romay-Penabad Z, Papalardo E , et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus 2012; 21 (14) 1497-1505
    CrossrefPubMedGoogle Scholar
  • 71 Agostinis C, Durigutto P, Sblattero D , et al. A non complement-fixing antibody to beta2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood 2014; 123: 3478-3487
    CrossrefPubMedGoogle Scholar
  • 72 Holers VM, Girardi G, Mo L , et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195 (2) 211-220
    CrossrefPubMedGoogle Scholar
  • 73 Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10 (11) 1222-1226
    CrossrefPubMedGoogle Scholar
  • 74 Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64 (8) 2719-2723
    CrossrefPubMedGoogle Scholar
  • 75 Thurman JM, Kraus DM, Girardi G , et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005; 42 (1) 87-97
    CrossrefPubMedGoogle Scholar
  • 76 Wirthmueller U, Dewald B, Thelen M , et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol 1997; 158 (9) 4444-4451
    PubMedGoogle Scholar
  • 77 Schwaeble WJ, Reid KB. Does properdin crosslink the cellular and the humoral immune response?. Immunol Today 1999; 20 (1) 17-21
    CrossrefPubMedGoogle Scholar
  • 78 Jankowski M, Vreys I, Wittevrongel C , et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101 (1) 157-162
    CrossrefPubMedGoogle Scholar